HALDRONE
LOE ApproachingNDAORALTABLET
Approved
Apr 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALDRONE is an oral small-molecule tablet approved by Eli Lilly in 1961 for an undisclosed indication. The mechanism of action and pharmacologic class are not publicly documented in available data. This is a legacy NDA product approaching loss of exclusivity.
LOE Approaching
With LOE approaching and zero linked job openings, commercial team size is likely minimal and focused on transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal minimal hiring activity; roles on HALDRONE are likely limited to product maintenance, regulatory compliance, and transition planning. Career growth opportunities are constrained by the product's LOE-approaching status and legacy market position.
Company
Worked on HALDRONE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.